Ankit Mahadevia is a principal in the life sciences group and focuses on novel drug discovery platforms, therapeutic products, and other medical technologies that meet a significant unmet clinical need.
Prior to joining Atlas in 2008, Ankit worked on product and business development with the founding team at Arcion Therapeutics. He has also held positions in business development both at Genentech and at Vanda Pharmaceuticals. Previously, he worked in the health care groups of McKinsey & Company and Monitor Group. Ankit began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office, and the Mexican Institute of Social Security (IMSS).
Ankit currently serves on the boards of Atlas companies Annovation Biopharma, RaNA Therapeutics, Lumavita, and Fibrex Medical. He also works closely with Arteaus Therapeutics, JenaValve, and Nimbus Discovery and previously worked with Sirion Therapeutics (acquired by Alcon and Bausch & Lomb). Ankit is also actively involved in the Shire/Atlas Venture Alliance and the Atlas/Monsanto Seed Fund Alliance.
Ankit received an MD from the Johns Hopkins University School of Medicine and an MBA from the Wharton School of the University of Pennsylvania. He received a BA in economics and biology, with honors, from Northwestern University, where he graduated summa cum laude.
Ankit was appointed by the U.S. Secretary of Health and Human Services to the Advisory Council of the NIH Center for Advancing Translational Sciences. He also serves on board of the Johns Hopkins Alliance for Technology Transfer, through which he promotes translation of biomedical research by biotechnology companies.
Ankit lives in Brookline, Massachusetts with his wife and two sons.